Unlearn, a biotech AI startup, secures $15 million and appoints OpenAI’s CTO to its board.

Biotech AI startup, Unlearn, has recently gained some notable support in the form of $15 million in funding and the addition of OpenAI’s Chief Technology Officer, Greg Brockman, to their board. As the healthcare industry continues to embrace the potential of artificial intelligence, Unlearn is at the forefront of developing technologies that can leverage data from clinical trials to improve patient outcomes. The recent investment and appointment of Brockman will undoubtedly propel Unlearn forward in their mission to revolutionize the way clinical trials are conducted and ultimately, help bring life-saving treatments to patients faster.


Unlearn.AI has raised $15 million to expand partnerships and speed up regulatory approval for its machine learning platform that creates “digital twin” profiles of patients in clinical trials. Radical Ventures and Wittington Ventures led the investment round, valuing the San Francisco-based startup at $265 million. Unlearn.AI has won approval from the European Medicines Agency for conducting smaller and quicker clinical trials using AI-driven methods. Its technology replaces patients who receive a placebo, potentially lowering costs for drug developers. Unlearn.AI has raised a total of $85 million from investors including 8VC, Insight Partners, and Mubadala Ventures. Microsoft-backed OpenAI’s CTO, Mira Murati, is joining the board at Unlearn.AI.


In the world of biotech, the intersection of artificial intelligence and innovative science could help to revolutionize healthcare as we know it. With Unlearn’s impressive $15 million funding round and the addition of OpenAI’s experienced CTO, Greg Brockman, to their board, the company is now poised to accelerate their efforts in this space. By leveraging the power of AI, Unlearn can continue to push the boundaries of medical research and fundamentally change the way we understand and treat complex diseases. With such exciting developments on the horizon, we’re eagerly anticipating what the future holds for this promising biotech startup.